Malondialdehyde in Exhaled Breath Condensate as a Marker of Oxidative Stress in Different Pulmonary Diseases
2011

Malondialdehyde in Exhaled Breath Condensate as a Marker of Oxidative Stress in Different Pulmonary Diseases

Sample size: 194 publication Evidence: moderate

Author Information

Author(s): Bartoli M. L., Novelli F., Costa F., Malagrinò L., Melosini L., Bacci E., Cianchetti S., Dente F. L., Di Franco A., Vagaggini B., Paggiaro P. L.

Primary Institution: University of Pisa, Ospedale di Cisanello

Hypothesis

The study aims to explore the usefulness of measuring malondialdehyde (MDA) levels in exhaled breath condensate (EBC) as a marker of oxidative stress in various pulmonary diseases.

Conclusion

MDA levels in exhaled breath condensate are increased in patients with chronic airway disorders, especially in COPD, and are related to the severity of airway obstruction.

Supporting Evidence

  • MDA levels were significantly higher in all disease groups compared to healthy controls.
  • COPD patients had the highest MDA levels among the disease groups.
  • Asthmatic patients treated with corticosteroids had lower MDA levels than untreated patients.
  • There was an inverse correlation between MDA concentrations and FEV1 in COPD patients.
  • Patients with high sputum neutrophils showed significantly higher MDA levels.

Takeaway

This study found that a substance called MDA, which shows how much stress is on the lungs, is higher in people with lung diseases like COPD and asthma.

Methodology

MDA levels were measured in exhaled breath condensate from 194 patients with various respiratory diseases and compared to 14 healthy controls.

Potential Biases

Potential bias may arise from the selection of patients and the methods used for measuring MDA.

Limitations

The study may not account for all confounding factors affecting MDA levels, and the sample size for some disease groups was relatively small.

Participant Demographics

Participants included 194 patients with asthma, bronchiectasis, COPD, and idiopathic pulmonary fibrosis, along with 14 healthy controls.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2011/891752

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication